Paecilomycotic toxic cardiomyopathy and myocardites in children
Paecilomycosis is a new mycosis, included in the WHO classification. For the first time, paecilomycotic heart pathology was studied in animals and humans. In particular, 218 children were examined, using various bacteriological, clinical, cardiological, biochemical, and immunological methods. In 150 white mice, an experiment paecilomycosis model was used to confirm the diagnosis and investigate the potential of various registered medications, identifying the most effective and the least toxic ones. According to evidence-based medicine principles, the clinical diagnoses of paecilomycotic cardiomyopathy and myocardites were specified. Aetiopathogenetic therapy with nizoral and immunomodulin improved clinical course of pecylomycotic heart disease, due to prevention of complications, chronisation, and long hospitalization time. The best treatment effectiveness in 4-7-year-old children with pecylomycotic cardiomyopathy and myocardites was observed for the combination of diflucan, mycosyst, cardiac glycosides from medicinal plants, and polyoxydonium.